Recent Updates
Recently added Catalysts

Avadel Pharmaceuticals plc

AVDL
OvervaluedPharma · Commercial
FDA catalysts, PDUFA dates & pipeline intelligence
$21.64
▼ -0.02 · -0.09%

Last traded Feb 11, 2026. This price is not current.

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full AVDL financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $6.3852W HIGH $23.57
Volume
35.02 M
Value Traded
758.22 M
Short % Float
2.61%
+0.19%Week
+0.7%1 Month
+13.54%3 Month
+59.82%6 Month
+133.69%5 Year
+80.33%All Time

Cash Data

Unlock AVDL cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
2.12 B
EPS (TTM)
-0.00
P/E Ratio
-
Ent. Value
2.06 B
Total Shares
97.14 M
Float Shares
88.49 M
Insiders
5.27%
Institutions
75.91%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
PDUFA
2026
Example Drug
Treatment for example condition requiring FDA review
Phase 3Small MoleculeOncology-
Unlock every AVDL catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

AVDL Catalyst Timeline

Dated clinical, regulatory and corporate events for Avadel Pharmaceuticals plc

Unlock the full AVDL catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How AVDL actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-06-30LUMRYZ (sodium oxybate) Phase 3 data readout Phase 3
Unlock 2 more AVDL historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

D35 / 100
Pipeline Score
$161M
Pipeline Value
$1.1B
Commercial Value
Overvalued
Valuation Signal
1
Drugs Scored
0.2x
rNPV / MCap
Avadel Pharmaceuticals plc faces pipeline headwinds (35/100), with $247M risk-adjusted pipeline value, led by Lumryz in Narcolepsy Type 1 (NT 1) (Phase 2).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-Q), to Sep 2025) Revenue $248.5M x 4.4 = $1.1B
Showing 1 of 1 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
Lumryz Small moleculeNCT06809803Narcolepsy Type 1 (NT 1)Phase 2 RECRUITING 36Jul 1, 2027
Unlock the AVDL pipeline intelligence model
Every scored asset with PTRS, rNPV, enrollment velocity and trial design quality.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every AVDL program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
LUMRYZ
Orphan
narcolepsyPhase 32025-09-05statistically significant and clinically meaningful improvements in the three co-primary endpointsRead MoreAvadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension at World Sleep 2025Read More
Scroll for more · summaries link to the source press release
Unlock every AVDL trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock AVDL insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Weiss Asset Management LPFormer 10% OwnerSell -11,112,052 $21.00 02/13/2026
Unlock the full AVDL insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in AVDL

Fund % of Portfolio Current MV Shares Owned Activity
Vivo Capital, LLC 3.7 % (12.1 %) 57.84 M 2.68 M
Unlock every fund holding AVDL
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in AVDL
Shares held by hedge funds each quarter, and who bought or sold.

AVDL Institutional Ownership Trends

Options Data

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock AVDL option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live AVDL option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock AVDL options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How AVDL ranks across every disease it competes in

Competitive Position is a premium feature
See how AVDL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

AVDL News

About Avadel Pharmaceuticals plc

Founded2015
BIOPHARMAWATCH ELITE PLUS
Trade the next AVDL catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime